MOSCOW (Sputnik) - The Russian Health Ministry has authorized phase 1 and 2 clinical trials of EpiVacCorona-N, one more coronavirus vaccine developed by the Vector research center, according to
MOSCOW (Sputnik) - The Russian Health Ministry has authorized phase 1 and 2 clinical trials of EpiVacCorona-N, one more coronavirus vaccine developed by the Vector research center, according to
MOSCOW (Sputnik) - A six-month neurological and psychiatric study released by The Lancet Psychiatry found that 33.62 percent of ex-COVID-19 patients had a neurological or psychological disorder
MOSCOW (Sputnik) - A six-month neurological and psychiatric study released by The Lancet Psychiatry found that 33.62 percent of ex-COVID-19 patients had a neurological or psychological disorder
MOSCOW (Sputnik) - A six-month neurological and psychiatric study released by The Lancet Psychiatry found that 33.62 percent of ex-COVID-19 patients had a neurological or psychological disorder
MOSCOW (Sputnik) - As many as 94 percent of senior citizens develop antibodies against the coronavirus after being inoculated with Russia's EpiVacCorona vaccine, the head of the Yekaterinburg de
MOSCOW (Sputnik) - As many as 94 percent of senior citizens develop antibodies against the coronavirus after being inoculated with Russia's EpiVacCorona vaccine, the head of the Yekaterinburg de
MOSCOW (Sputnik) - As many as 94 percent of senior citizens develop antibodies against the coronavirus after being inoculated with Russia's EpiVacCorona vaccine, the head of the Yekaterinburg de
MOSCOW (Sputnik) - As many as 94 percent of senior citizens develop antibodies against the coronavirus after being inoculated with Russia's EpiVacCorona vaccine, the head of the Yekaterinburg de
MOSCOW (Sputnik) - As many as 94 percent of senior citizens develop antibodies against the coronavirus after being inoculated with Russia's EpiVacCorona vaccine, the head of the Yekaterinburg de
